Drug Trial Radar · NCT07033494
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
340
Planned (sponsor's estimate)
Start
Jul 16, 2025
Primary completion
Apr 30, 2029
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it
Conditions
- Early Alzheimer's Disease
Interventions
MK-2214Biological
IV infusion
PlaceboDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Base Period: Change from Baseline in Tau PET Standardized Uptake Value Ratio (SUVr)Time frame: Baseline, up to approximately 23 months
- Base Period: Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 26 months
- Base Period: Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 23 months
Locations
80 sites in 11 countries. Site status is shown where the registry gives one.
Irvine Clinical Research ( Site 1041)
Irvine, California · Recruiting
Healthy Brain Clinic ( Site 1005)
Long Beach, California · Recruiting
Inglewood Clinical ( Site 1062)
Los Angeles, California · Recruiting
Anderson Clinical Research ( Site 1024)
Redlands, California · Recruiting
UCSF Memory and Aging Center ( Site 1031)
San Francisco, California · Recruiting
Syrentis Clinical Research ( Site 1001)
Santa Ana, California · Recruiting
Yale University, Alzheimer's Disease Research Unit ( Site 1059)
New Haven, Connecticut · Recruiting
JEM Research Institute ( Site 1046)
Atlantis, Florida · Recruiting
Neuropsychiatric Research Center of Southwest Florida ( Site 1003)
Fort Myers, Florida · Recruiting
K2 Medical Research ( Site 1047)
Maitland, Florida · Recruiting
ClinCloud LLC ( Site 1039)
Melbourne, Florida · Recruiting
Indago Research and Health Center Inc ( Site 1044)
Miami Lakes, Florida · Recruiting
Aqualane Clinical Research ( Site 1035)
Naples, Florida · Recruiting
Suncoast Clinical Research ( Site 1007)
New Port Richey, Florida · Recruiting
Renstar Medical Research ( Site 1012)
Ocala, Florida · Recruiting
Charter Research - Orlando ( Site 1051)
Orlando, Florida · Recruiting
Axiom Brain Health ( Site 1029)
Tampa, Florida · Recruiting
K2 Medical Research ( Site 1020)
Tampa, Florida · Recruiting
Charter Research - Lady Lake ( Site 1019)
The Villages, Florida · Recruiting
Conquest Research LLC ( Site 1053)
Winter Park, Florida · Recruiting
CenExel iResearch, LLC ( Site 1015)
Decatur, Georgia · Recruiting
Alexian Brothers Medical Center-Neurosciences ( Site 1017)
Elk Grove Village, Illinois · Recruiting
Boston Center for Memory ( Site 1008)
Newton, Massachusetts · Recruiting
Clinical Research Professionals ( Site 1004)
Chesterfield, Missouri · Completed
CenExel- AMRI ( Site 1018)
Marlton, New Jersey · Recruiting
The Cognitive and Research Center of New Jersey - Ridgewood ( Site 1064)
Ridgewood, New Jersey · Recruiting
The Cognitive and Research Center of NJ ( Site 1057)
Springfield, New Jersey · Recruiting
Alzheimer Disease Research Center (ADRC) ( Site 1000)
Albany, New York · Recruiting
Mid Hudson Medical Research ( Site 1050)
New Windsor, New York · Recruiting
Basil Clinical ( Site 1065)
Queens, New York · Recruiting
AMC Research, LLC ( Site 1006)
Matthews, North Carolina · Recruiting
Insight Clinical Trials ( Site 1011)
Independence, Ohio · Recruiting
Neuro-Behavioral Clinical Research ( Site 1028)
North Canton, Ohio · Recruiting
Flourish Research ( Site 1048)
Plymouth Meeting, Pennsylvania · Recruiting
Gadolin Research ( Site 1032)
Beaumont, Texas · Recruiting
Horizon Clinical Research Center - Houston ( Site 1026)
Cypress, Texas · Recruiting
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) ( Site 0400)
Caba, Argentina · Recruiting
Organizacion Medica de Investigacion ( Site 0401)
Ciudad de Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0404)
Ciudad de Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Southern Neurology ( Site 0306)
Kogarah, New South Wales, Australia · Recruiting
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.